drugset / Trial / NCT00033462
Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer
NaSingle-groupOpen-labelTreatment
Summary
Phase II trial to study the effectiveness of erlotinib in treating patients who have unresectable liver, bile duct, or gallbladder cancer. Biological therapies such as erlotinib may interfere with the growth of cancer cells and slow the growth of the tumor.
Timeline
- Start
- 2002-03
- Primary completion
- 2006-11
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Erlotinib | Small molecule | — | Oral |